Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2023 –2030 | |
|
|
USD 1.23 Billion |
| USD 1.63 Billion | |
| % | |
|
Global Hypertrophic Cardiomyopathy Treatment Market, By Disease Type (Obstructive Hypertrophic cardiomyopathy treatment and Non-obstructive Hypertrophic cardiomyopathy treatment), Diagnosis (Chest X-Ray, Echocardiogram, Electrocardiogram (ECG), Treadmill Stress Test, Cardiac Catheterization, Cardiac MRI, Cardiac CT Scan, Blood Tests, Genetic Testing Or Screening), Treatment (Medication, Surgically Implanted Devices, Nonsurgical Procedures, Surgery), End-User (Hospitals, Research Institutes, Specialty Clinics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2030.
The hypertrophic cardiomyopathy treatment market is projected to witness significant growth during the forecast period. Demand for Hypertrophic cardiomyopathy treatment (HCM) therapeutics is estimated to grow during the forecast period, due to increasing incidence of hypertrophic cardiomyopathy treatment globally. In few people, a number of other related conditions may develop due to HCM, including abnormal heart rhythms or arrhythmias, heart block, and endocarditis.
Data Bridge Market Research analyses a growth rate in the hypertrophic cardiomyopathy treatment market in the forecast period 2023-2030. The expected CAGR of hypertrophic cardiomyopathy treatment market is tend to be around 3.60% in the mentioned forecast period. The market was valued at USD 1.23 billion in 2022, and it would grow upto USD 1.63 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Type (Obstructive Hypertrophic cardiomyopathy treatment and Non-obstructive Hypertrophic cardiomyopathy treatment), Diagnosis (Chest X-Ray, Echocardiogram, Electrocardiogram (ECG), Treadmill Stress Test, Cardiac Catheterization, Cardiac MRI, Cardiac CT Scan, Blood Tests, Genetic Testing Or Screening), Treatment (Medication, Surgically Implanted Devices, Nonsurgical Procedures, Surgery),End-User (Hospitals, Research Institutes, Specialty Clinics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Alexion Pharmaceuticals, Inc. (U.S.), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), Vertex Pharmaceuticals Incorporated (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), Amgen Inc. (U.S.), Jazz Pharmaceuticals, Inc. (U.K.), Pfizer Inc (U.S.), PerkinElmer Inc (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), GSK plc (U.K.), Hikma Pharmaceuticals PLC (U.K.), Cipla Inc. (India), Lupin (India)
|
|
Market Opportunities
|
|
Market Definition
Hypertrophic cardiomyopathy treatment (HCM) is a kind of disease in which the heart muscle gets abnormally thick. The thickened heart muscle makes it difficult for the heart to pump the blood. Cardiomyopathy can affect any age group and result in lifelong disease consequences. Some of the main symptoms of hypertrophic cardiomyopathy treatment are shortness of breath, chest pain, fainting, palpitations, and light headaches.
Drivers
According to the American Heart Association (AHA), in March 2016, hypertrophic cardiomyopathy treatment affected about 500,000 people in the U.S annually. Additionally, according to the European Heart Journal, July 2014 findings, HCM occurs in 1:500 people in the general population globally, which reported about 700,000 affected Americans. Additionally, about 2 million people in India and China are affected with hypertrophic cardiomyopathy treatment.
Major market players in the market are focusing on organic growth strategies such as collaborations and regulatory product approval to gain maximum market share and retain the leading position in the market. For instance, in September 2014, Sanofi S.A. and MyoKardia, Inc. collaborated to discover and develop targeted therapeutics for genetic heart diseases such as cardiomyopathy, hypertrophic cardiomyopathy treatment, and dilated cardiomyopathy (DCM).
Opportunities
Overweight patients were related with more heart failure (HF) rehospitalization in HCM patients and being overweight was an independent determinant of major serious cardiovascular and cerebral events (MACCE) in HCM patients. Therefore, the burden of obesity and overweight along with the risk of heart failure among hypertrophic cardiomyopathy treatment (HCM) patients with obesity demands the availability of therapeutics for treatment. Thus driving the market growth.
The market's growth is boosted by an increase in the number of R&D activities. Increasing number of research studies in the field of hypertrophic cardiomyopathy treatment treatment by several private and government organizations develop treatment option such as calcium channel blockers and antiarrhythmic agent. For instance, in May 2018, MyoKardia, Inc. initiated the PIONEER open-label extension (OLE) study of its investigational drug: mavacamten, which is to be used in symptomatic, obstructive hypertrophic cardiomyopathy treatment. Additionally, according to a study published in Journal of General Physiology in May 2018, researchers from Washington State University discovered link between genetic mutation to hypertrophic cardiomyopathy treatment (HCM) and mode of disrupting the heart’s normal function.
Restraints/Challenges
In the developing economies such as China and India, lack of private or governmental medical insurance programmes create major healthcare delivery barrier for cardiac patients who requires longitudinal care and expensive technology such as open heart surgery and implantable Cardioverter Defibrillators (ICDs). Thus, it hampers the market growth
The huge expenditure required for the treatment processes surely impede the market growth. Several market players make huge investments in installing new and advanced treatment procedures to faster the recovery process and in return the cost is increased.
This hypertrophic cardiomyopathy treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hypertrophic cardiomyopathy treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments:
The hypertrophic cardiomyopathy treatment market is segmented on the basis of disease type, diagnosis, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease Type
Diagnosis
Treatment
End-User
Distribution Channel
The hypertrophic cardiomyopathy treatment market is analyzed and market size insights and trends are provided by disease type, diagnosis, treatment, distribution channel and end-user as referenced above.
The major countries covered in the hypertrophic cardiomyopathy treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market due to the increase in the incidence of heart diseases such as coronary heart disease and heart attack.
Asia-Pacific is expected to grow during the forecast period due to the rise in the medical tourism in emerging countries such as China and India.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
The hypertrophic cardiomyopathy treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hypertrophic cardiomyopathy treatment market
Key players operating in the hypertrophic cardiomyopathy treatment market include:
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.